http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2012153177-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4515 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-451 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0095 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-221 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-138 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-165 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-335 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-341 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-635 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-655 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-549 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-335 |
| filingDate | 2011-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2012153177-A |
| titleOfInvention | COMPOSITIONS OF LOW-MOLECULAR THERAPEUTIC MEDICINES |
| abstract | 1. A composition comprising a low molecular weight therapeutic agent and an alkyl (N, N-disubstituted amino) acetate. The composition according to claim 1, characterized in that the low molecular weight therapeutic agent is selected from the group consisting of taxane and a compound belonging according to the biopharmaceutical classification system (BCS) to at least one of classes 2, 3 or 4.3. The composition according to claim 2, wherein the taxane is a member of the group consisting of paclitaxel, docetaxel, tesetaxel and mixtures thereof. The composition according to claim 2, characterized in that the said compound belongs to class 2 of BCS. 5. A composition according to claim 4, characterized in that said compound is selected from the group consisting of lansoprazole, haloperidol, sulfasalazine and glibenclamide. The composition according to claim 2, characterized in that the said compound belongs to class 3 of BCS. 7. The composition of claim 6, wherein said compound is selected from the group consisting of atenolol, glucosamine or a salt thereof and cimetidine. The composition according to claim 2, characterized in that the said compound belongs to class 4 of BCS. 9. The composition of claim 8, wherein the compound is selected from the group consisting of furosemide, chlortiazide and hydrochlorothiazide. The composition of claim 1, further comprising a physiologically acceptable carrier. The composition according to claim 1, wherein the alkyl (N, N-disubstituted amino) acetate is dodecyl-2- (N, N-dimethylamino) propionate. The composition according to claim 1, wherein the alkyl (N, N-disubstituted amino) acetate is dodecyl-2- (N, N-dimethylamino) propionate hydrochloride. The composition according to claim 1, characterized in that the low molecular weight therapeutic agent |
| priorityDate | 2010-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 57.